Glucagon-like peptide-1 (GLP-1) agonists are a class of medication utilized to treat obesity and type 2 diabetes. Some examples include Exenatide, Liraglutide, Dulaglutide, and Semaglutide. GLP-1 agonists act by lowering serum glucose levels and thereby manage metabolism in affected patients (1). Glucagon-like peptide-1 (GLP-1) agonists are rapidly becoming central to evidence-based treatment of obesity. These agents not only offer substantial and sustained weight loss but a